Barry D. Quart
2023
In 2023, Barry D. Quart earned a total compensation of $4M as Former Chief Executive Officer at Heron Therapeutics, a 252% increase compared to previous year.
Compensation breakdown
| Option Awards | $1,625,625 |
|---|---|
| Salary | $188,501 |
| Stock Awards | $788,615 |
| Other | $1,427,606 |
| Total | $4,030,347 |
Quart received $1.6M in option awards, accounting for 40% of the total pay in 2023.
Quart also received $188.5K in salary, $788.6K in stock awards and $1.4M in other compensation.
Rankings
In 2023, Barry D. Quart's compensation ranked 182nd out of 2,907 executives tracked by ExecPay. In other words, Quart earned more than 93.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 182 out of 2,907 | 94th |
Division Manufacturing | 96 out of 1,599 | 94th |
Major group Chemicals And Allied Products | 61 out of 901 | 93rd |
Industry group Drugs | 60 out of 864 | 93rd |
Industry Pharmaceutical Preparations | 41 out of 622 | 93rd |
Source: SEC filing on April 29, 2024.
Quart's colleagues
We found four more compensation records of executives who worked with Barry D. Quart at Heron Therapeutics in 2023.
News
Heron Therapeutics CEO Craig Collard receives $11M in 2023
April 29, 2024
Heron Therapeutics Executive Vice President, Drug Development Kimberly Manhard's 2022 pay falls 22% to $1.4M
May 1, 2023
Heron Therapeutics CEO Barry Quart's 2021 pay rises 2% to $5.4M
April 25, 2022
Heron Therapeutics CEO Barry Quart's 2020 pay slips 9% to $5.3M
April 22, 2021
Heron Therapeutics CEO Barry Quart's 2019 pay slips 2% to $5.9M
April 23, 2020